The global upper respiratory tract infection treatment market is expected to grow at a significant CAGR during the forecast period (2021-2027). Upper respiratory tract infection (URTI) is a medical illness caused by an acute infection in the upper respiratory tract, which includes the larynx, pharynx, sinuses, and nose. Some of the most common upper respiratory tract illnesses include pharyngitis, sinusitis, laryngitis, tonsillitis, the common cold, and otitis media. The direct penetration of the mucus barrier by bacteria or viruses causes upper respiratory tract diseases. Some of the most common symptoms seen in individuals with upper respiratory tract illnesses include sneezing, rhinorrhea, nasal congestion, sore throat, nasal discharge, cough, fever, malaise, and odynophagia. Headache, hyposmia, bad breath, sinus pain, shortness of breath, vomiting, diarrhoea, nausea, conjunctivitis, and body aching are some of the other symptoms of the disease.

Antibiotics and decongestants can be used to treat upper respiratory tract infections. Antibiotics prescribed to patients with upper respiratory tract problems include acetaminophen, diphenhydramine, ibuprofen, dextromethorphan, guaifenesin, codeine, dexamethasone, and prednisone. The most widely prescribed decongestants for upper respiratory tract problems include phenylephrine, oxymetazoline, and pseudoephedrine. Antibiotics are rarely used to treat upper respiratory tract infections since they have a number of negative effects and can lead to secondary infections and bacterial resistance. The rise in the occurrence of respiratory ailments around the world is expected to drive the global upper respiratory tract infection treatment market. Furthermore, the risk of acquiring upper respiratory tract illnesses has been exacerbated by continually changing climatic circumstances as a result of global warming and pollution. Furthermore, the global upper respiratory tract infection treatment market is expected to develop as people's lifestyles change and medical insurance coverage expands. The individuals become more aware of their health and spend more money on personal cleanliness. The market is expected to rise owing to favourable reimbursement conditions and advanced medical infrastructure in developed countries. However, the market's expansion is projected to be hampered by NSAID side effects.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Upper Respiratory Tract Infection Treatment Market Report Segmentation

By Treatment Type

• Topical Treatment

• Drug Treatment

By Distribution Channel 

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Global Upper Respiratory Tract Infection Treatment Market by Region